Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ProShares Ultra Nasdaq Biotechnology (BIB)

51.28
Delayed Data
As of Aug 21
 +0.27 / +0.53%
Today’s Change
35.00
Today|||52-Week Range
60.19
+28.49%
Year-to-Date

Investment Objective

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index ®. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

No recent news for ProShares Ultra Nasdaq Biotechnology.

Performance

1 month-12.32% 3 years+1.66%
3 months+8.74% 5 years+30.19%
1 year+4.29% Since inception+29.80%
Data through 08/22/2017

Quote Details

Previous close$51.01
Open day’s range50.57 – 51.61
Net asset value (NAV)51.25 (08/21/2017)
Daily volume149,347
Average volume (3 months)281,706
Data as of 08/21/2017

Peer Comparisonvs. Trading--leveraged equity ETFs

 BIBCategory
Performance 5-yr return+30.19%+16.48%
Expense Gross exp ratio1.03%2.02%
Risk 5 year sharpe ratio0.86--
Net assets$453.4M$68.1M
Average market cap$19.4B--
Average P/E22.6--
Dividend / Share--0.31%

Competitors

SFLA iPath® Long Extended S&P 500® TR Index...
SDYL UBS ETRACS Monthly Pay 2xLeveraged S&P D...
SPLX UBS ETRACS Monthly Reset 2xLeveraged S&P...

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
-- 37.79%
-- 26.12%
-- 25.82%
-- 15.05%
CELG Celgene6.47%
GILD Gilead Sciences6.41%
BIIB Biogen6.39%
AMGN Amgen6.14%
-- 5.86%
REGN Regeneron Pharmaceuticals5.62%